-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inaticabtagene Autoleucel in Acquired (Autoimmune) Hemolytic Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inaticabtagene Autoleucel in Acquired (Autoimmune) Hemolytic Anemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inaticabtagene Autoleucel in Acquired (Autoimmune) Hemolytic Anemia Drug...
-
Product Insights
Dermatomyositis – Drugs In Development, 2023
Global Markets Direct’s, ‘Dermatomyositis - Drugs In Development, 2023’, provides an overview of the Dermatomyositis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Drugs In Development, 2023’, provides an overview of the Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Lupus Nephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Lupus Nephritis - Drugs In Development, 2023’, provides an overview of the Lupus Nephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Thrombocytopenia – Drugs In Development, 2023
Global Markets Direct’s, ‘Thrombocytopenia - Drugs In Development, 2023’, provides an overview of the Thrombocytopenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thrombocytopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Primary Mediastinal B-Cell Lymphoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Mediastinal B-Cell Lymphoma - Drugs In Development, 2023’, provides an overview of the Primary Mediastinal B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Mediastinal B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) - Drugs In Development, 2023’, provides an overview of the B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Thematic Analysis
State of the Biopharmaceutical Industry in 2024 – Thematic Intelligence
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you in: Examining the current attitudes of business leaders toward the emerging trends impacting the biopharmaceutical industry in the next 12 months. Benchmarking the impact of major themes on the biopharmaceutical industry in 2024, including emerging technologies, regulatory trends, macroeconomic trends, and industry trends. Identifying the most impactful anticipated regulatory approvals and drug launches in the industry in 2024, learning about top-selling drugs (2023 vs 2024), and obtaining...
-
Sector Analysis
Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Accessing in-depth insights from the ‘Acute Lymphocytic Leukemia Cell Therapy Market’ report will help you: Assess the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China) and identify the potential countries for growth opportunities within the ALL-cell therapy market. Analyze the clinical and commercial landscapes of each indication, with pricing assumptions Evaluate indication-specific unmet needs and competitive assessments by Class of Therapy Identify the Likelihood of Approval Analysis...